Olverembatinib (HQP1351) Overcomes Ponatinib and/or Asciminib Resistance in Patients With Heavily Pretreated/Refractory Chronic Myeloid Leukemia (CML) and Philadelphia Chromosome–Positive Acute Lymphoblastic Leukemia (Ph+ ALL)
Year: 2024
Type: article
Authors: Elias Jabbour, Vivian G. Oehler, Paul B. Koller, Omer Jamy, Elza Lomaia, Anthony M. Hunter, Olga Uspenskaya, Svetlana Samarina, Sudipto Mukherjee, Jorge E. Cortes, Maria R. Baer, Vera Zherebtsova, Vasily Shuvaev, Anna Turkina, Igor Davydkin, Huanshan Guo, Zi Chen, Tommy Fu, Lixin Jiang, Cunlin Wang, Hengbang Wang, Dajun Yang, Yifan Zhai, Hagop Kantarjian
Institutions: The University of Texas MD Anderson Cancer Center, Fred Hutch Cancer Center, City Of Hope National Medical Center, University of Alabama at Birmingham, UAB Medicine, National Medical Research Center for Hematology, Emory University, Winship Cancer Institute, Kirov Research Institute of Hematology and Blood Transfusion FMBA, Federal Medical-Biological Agency, Cleveland Clinic, Augusta University, University of Maryland, Baltimore, University of Maryland Marlene and Stewart Greenebaum Comprehensive Cancer Center, Botkin Hospital, City Clinical Hospital, Russian Research Institute of Hematology and Transfusiology, Samara State Medical University, Ascentage Pharma Group Inc. (United States), Sun Yat-sen University, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China
Language: English
Subfield: Hematology
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W4401896315